The final, formatted version of the article will be published soon.
BRIEF RESEARCH REPORT article
Front. Allergy
Sec. Asthma
Volume 5 - 2024 |
doi: 10.3389/falgy.2024.1420679
Biologic agents in idiopathic hypereosinophilic syndrome: a case series
Provisionally accepted- Department of Respiratory Medicine, General University Hospital of Patras, Pátrai, Greece
Background: Hypereosinophilic syndrome (HES) is a heterogeneous group of rare disorders defined by the presence of marked eosinophilia resulting in end organ damage. Treatment goals include reduction of flares and eosinophils with minimal drug related side-effects. The aim of this study was to present clinical, laboratory, functional features and outcomes in patients with idiopathic HES treated with biologic agents targeting eosinophils.Patients with idiopathic HES treated with anti-eosinophilic agent between 01/10/2019 and 01/10/2023 were retrospectively included in the study.Results: Eleven patients (n=11) with diagnosis of idiopathic HES were included in the study [M/F: 6/5, median age: 54 (95% CI: 38.2 to 68.5), smokers/never smokers: 5/6]. Asthma was present in majority of them (n=8, 72.7%,), four patients (n=4, 36.4%) presented with eosinophilic pleural effusions, two patients (n=2, 18.2%) with cardiac arrhythmias and one with bilateral eyelid angioedema. Eight patients (72.7%) were treated with mepolizumab (300 mg/month) and 3 (27.3%) with benralizumab (30 mg/4 weeks). Median values of eosinophils at baseline and 12 months after initiation of biologic agent were 3000 (95% CI: 2172 to 11365) K/μL and 50 (95% CI: 3 to 190) K/μL, respectively. All patients with concomitant asthma (n=8) experienced elimination of asthma flares, asthma control (ACQ<0.75), functional improvement (mean ΔFEV1: 857 ± 594 ml) and 82% reduction in oral corticosteroids.Biologic agents in patients with idiopathic HES are both safe and effective sparing toxicity of immunosuppressive agents. Real-life data from larger registries are greatly anticipated.
Keywords: Hypereosinophilic Syndrome, Biologic agents, Eosinophils, Flare, corticosteroids
Received: 20 Apr 2024; Accepted: 04 Jun 2024.
Copyright: © 2024 Papaioannou, Karampitsakos, Sampsonas and Tzouvelekis. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Argyrios Tzouvelekis, Department of Respiratory Medicine, General University Hospital of Patras, Pátrai, Greece
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.